ArticleInvestigative ophthalmology & visual science2025
Clinical Manifestations and Ophthalmic Outcomes of Leukemic Retinopathy and Optic Neuropathy in Patients With Acute Leukemia.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Visual Clues in Ocular Involvement of Acute Promyelocytic LeukemiaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Molecular and Biomechanical Changes in the Anterior Segment of High Myopic Eyes.Annals of biomedical engineering · 2026Review
- Case Report: An interesting case of vision and hearing loss revealing CNS recurrence in Philadelphia-positive acute lymphoblastic leukemia.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the clinical manifestations and visual outcomes of leukemic retinopathy and optic neuropathy (LRON) in patients with acute leukemia. Methods: We recruited 276 patients with acute leukemia, 55 of whom had LRON. The ophthalmic measurements, treatment courses, laboratory data, and molecular profiling were retrospectively collected. Results: Patients with LRON were classified as type 1, type 2a, type 2b, and type 3. All patients with type 3 LRON had acute lymphoblastic leukemia (ALL), while the other types of LRON mainly occurred in patients with acute myeloid leukemia (AML). Patients with type 2b and type 3 LRON had worse initial best-corrected visual acuity (BCVA); none of the patients with type 3 LRON had recovery of BCVA during follow-up. The patients with AML with LRON were more likely to undergo hematopoietic stem cell transplantation (P < 0.001); their leukemic blasts more frequently expressed CD7 (P = 0.004) and CD38 (P = 0.048) and harbored DNMT3A (P = 0.017) and IDH1 (P = 0.041) mutations. Notably, the co-occurrence of DNMT3A, IDH1, and TET2 mutations was associated with a particularly high risk of LRON (odds ratio = 16.41). The patients with ALL with type 3 LRON had higher rates of central nervous system involvement (P = 0.041) and relapsed leukemia (P = 0.007). Nevertheless, the presence of LRON did not significantly affect survival in acute leukemia. Conclusions: We characterized distinct clinical, genetic features and visual outcomes across LRON subtypes. Our study highlights the importance of prompt ophthalmic consultation and patient education regarding visual symptoms in acute leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.